Anti-VTCN1, AlpHcAbs® Human antibody

Details and Advantages

Code: 300-784-001

Specification:

Applications: ELISA,Flow Cyt

Reactivity: Human

Conjugate: Unconjugated

Advantages:

High lot-to-lot consistency Increased sensitivity and higher affinity Animal-free production

Product Description Manual MSDS FAQ Citations

Product Detail

Description:
Anti-VTCN1, AlpHcAbs® Human antibody is designed for detecting human VTCN1 specifically. Based on ELISA and/or FCM, Anti-VTCN1, AlpHcAbs® Human antibody reacts with human VTCN1 specifically.

Immunogen: Recombinant human VTCN1
Host: Alpaca pacous
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human VTCN1
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles)

Background:
B7-H4 (B7x, VTCN1) a costimulatory protein which is reported to function as a negative regulator of T-cell mediated immunity. Although B7-H4 binds an unknown receptor, it is thought to deliver an inhibitory signal to T-cells preventing their proliferation, cell cycle progression and interleukin-2 production. B7-H4 deficient mice are only minimally affected; suggesting B7-H4 is important in the fine tuning of the T-cell mediated immune response. B7-H4 is expressed on activated T-cells, B-cells, monocytes and dendritic cells. Aberrant expression has been associated with cancers of the lung, breast and ovary in humans. B7-H4 is expressed primarily on the membrane of lymphoid cells, and as an immunoinhibitory protein that interacts with receptors on the surface of T lymphocytes, it is involved in mediating cellular and humoral immune responses. Overexpression of B7-H4 is associated with certain malignancies, including ovarian and breast cancer, which may be a mechanism by which tumor cells suppress T cell immunity and facilitate tumor progression. Further, VTCN1 may be a useful biomarker for the early detection of ovarian cancer and Renal Cell Carcinoma (RCC).

FAQ

Citations